The Donut Hole Dilemma: Retaining Lost Patients Under Medicare Part D
This article was originally published in RPM Report
Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large number of the industry's best customers do reduce their medication use in the donut hole-and if a customer is lost to the donut hole, they may be lost for good.
You may also be interested in...
It's not often than any industry group voluntarily agrees to give up $80 billion in future revenues, but that's what the Pharmaceutical Research & Manufacturers of America is pledging to do to in the context of the health care reform debate. There are a lot of details to work out, but this is a case where what is important is not what PhRMA is giving-but what it gets.
The key part of PhRMA's deal with the Finance Committee is a double win for industry: assuring that closing the donut hole will be part of reform, and that PhRMA will get credit for a big part of the savings.
Playing for high stakes is fun, but not if you find yourself matched against bigger players who are holding all the cards. That must by how Sierra Health Systems feels after being cleaned out by the two Medicare goliaths, Humana and UnitedHealth Group.